Logo image of SYRS

SYROS PHARMACEUTICALS INC (SYRS) Stock Fundamental Analysis

NASDAQ:SYRS - Nasdaq - US87184Q2066 - Common Stock - Currency: USD

0.1172  -0.01 (-8.44%)

After market: 0.1072 -0.01 (-8.53%)

Fundamental Rating

1

Taking everything into account, SYRS scores 1 out of 10 in our fundamental rating. SYRS was compared to 561 industry peers in the Biotechnology industry. Both the profitability and financial health of SYRS have multiple concerns. SYRS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SYRS has reported negative net income.
In the past year SYRS has reported a negative cash flow from operations.
SYRS had negative earnings in each of the past 5 years.
SYRS had a negative operating cash flow in each of the past 5 years.
SYRS Yearly Net Income VS EBIT VS OCF VS FCFSYRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -115.08%, SYRS is doing worse than 78.77% of the companies in the same industry.
Industry RankSector Rank
ROA -115.08%
ROE N/A
ROIC N/A
ROA(3y)-61.3%
ROA(5y)-54.72%
ROE(3y)-387.81%
ROE(5y)-270.29%
ROIC(3y)N/A
ROIC(5y)N/A
SYRS Yearly ROA, ROE, ROICSYRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

SYRS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SYRS Yearly Profit, Operating, Gross MarginsSYRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

2

2. Health

2.1 Basic Checks

SYRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
SYRS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SYRS has more shares outstanding
The debt/assets ratio for SYRS is higher compared to a year ago.
SYRS Yearly Shares OutstandingSYRS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
SYRS Yearly Total Debt VS Total AssetsSYRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -16.26, we must say that SYRS is in the distress zone and has some risk of bankruptcy.
SYRS has a worse Altman-Z score (-16.26) than 82.98% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -16.26
ROIC/WACCN/A
WACC9.28%
SYRS Yearly LT Debt VS Equity VS FCFSYRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 2.25 indicates that SYRS has no problem at all paying its short term obligations.
SYRS has a worse Current ratio (2.25) than 72.98% of its industry peers.
SYRS has a Quick Ratio of 2.25. This indicates that SYRS is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.25, SYRS is not doing good in the industry: 71.23% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.25
Quick Ratio 2.25
SYRS Yearly Current Assets VS Current LiabilitesSYRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.20% over the past year.
The Revenue for SYRS has decreased by -95.61% in the past year. This is quite bad
Measured over the past years, SYRS shows a very strong growth in Revenue. The Revenue has been growing by 37.12% on average per year.
EPS 1Y (TTM)19.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.81%
Revenue 1Y (TTM)-95.61%
Revenue growth 3Y-13%
Revenue growth 5Y37.12%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 7.05% on average over the next years.
Based on estimates for the next years, SYRS will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y73.44%
EPS Next 2Y35.34%
EPS Next 3Y23.72%
EPS Next 5Y7.05%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-47.5%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SYRS Yearly Revenue VS EstimatesSYRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2026 2027 2031 2032 5M 10M 15M 20M
SYRS Yearly EPS VS EstimatesSYRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SYRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SYRS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYRS Price Earnings VS Forward Price EarningsSYRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYRS Per share dataSYRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

SYRS's earnings are expected to grow with 23.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.34%
EPS Next 3Y23.72%

More info and screens

0

5. Dividend

5.1 Amount

SYRS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYROS PHARMACEUTICALS INC

NASDAQ:SYRS (3/19/2025, 8:16:43 PM)

After market: 0.1072 -0.01 (-8.53%)

0.1172

-0.01 (-8.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25 2025-03-25/amc
Earnings (Next)05-12 2025-05-12/bmo
Inst Owners24.37%
Inst Owner Change-86.09%
Ins Owners0.78%
Ins Owner Change-2.15%
Market Cap3.14M
Analysts77.78
Price Target10.71 (9038.23%)
Short Float %1.24%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.44%
Min EPS beat(2)24.66%
Max EPS beat(2)78.21%
EPS beat(4)3
Avg EPS beat(4)26.22%
Min EPS beat(4)-86.73%
Max EPS beat(4)88.72%
EPS beat(8)5
Avg EPS beat(8)22.54%
EPS beat(12)8
Avg EPS beat(12)17.39%
EPS beat(16)11
Avg EPS beat(16)15.77%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-95.26%
Min Revenue beat(4)-100%
Max Revenue beat(4)-81.03%
Revenue beat(8)0
Avg Revenue beat(8)-67.21%
Revenue beat(12)3
Avg Revenue beat(12)-38.68%
Revenue beat(16)7
Avg Revenue beat(16)-14.54%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)6.7%
EPS NQ rev (3m)3.7%
EPS NY rev (1m)4.86%
EPS NY rev (3m)3.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.15
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.03
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-3.73
FCFYN/A
OCF(TTM)-3.73
OCFYN/A
SpS0.01
BVpS-0.41
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -115.08%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.3%
ROA(5y)-54.72%
ROE(3y)-387.81%
ROE(5y)-270.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.25
Quick Ratio 2.25
Altman-Z -16.26
F-Score0
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)31.74%
Cap/Depr(5y)133.96%
Cap/Sales(3y)5.46%
Cap/Sales(5y)135.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.81%
EPS Next Y73.44%
EPS Next 2Y35.34%
EPS Next 3Y23.72%
EPS Next 5Y7.05%
Revenue 1Y (TTM)-95.61%
Revenue growth 3Y-13%
Revenue growth 5Y37.12%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-47.5%
Revenue Next 5Y-14.87%
EBIT growth 1Y17.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13%
OCF growth 3YN/A
OCF growth 5YN/A